Skip to main content

A double blind, randomised, placebo-controlled trial evaluating efficacy and safety of oral nintedanib treatment for at least 52 weeks in patients with `Systemic Sclerosis associated Interstitial Lung Disease'(SSc-ILD).

Clinical Trial Grant
Duke Scholars

Administered By

Medicine, Rheumatology and Immunology

Awarded By

Boehringer Ingelheim Pharmaceuticals, Inc.

Start Date

August 15, 2016

End Date

August 14, 2019
 

Administered By

Medicine, Rheumatology and Immunology

Awarded By

Boehringer Ingelheim Pharmaceuticals, Inc.

Start Date

August 15, 2016

End Date

August 14, 2019